164 related articles for article (PubMed ID: 22227023)
1. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
van der Meel R; Oliveira S; Altintas I; Haselberg R; van der Veeken J; Roovers RC; van Bergen en Henegouwen PM; Storm G; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2012 Apr; 159(2):281-9. PubMed ID: 22227023
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of tumor growth by targeted anti-EGFR/IGF-1R nanobullets depends on efficient blocking of cell survival pathways.
van der Meel R; Oliveira S; Altintas I; Heukers R; Pieters EH; van Bergen en Henegouwen PM; Storm G; Hennink WE; Kok RJ; Schiffelers RM
Mol Pharm; 2013 Oct; 10(10):3717-27. PubMed ID: 23889133
[TBL] [Abstract][Full Text] [Related]
3. Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.
Tandon R; Kapoor S; Vali S; Senthil V; Nithya D; Venkataramanan R; Sharma A; Talwadkar A; Ray A; Bhatnagar PK; Dastidar SG
Eur J Pharmacol; 2011 Sep; 667(1-3):56-65. PubMed ID: 21640718
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
[TBL] [Abstract][Full Text] [Related]
5. Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells.
Cunningham MP; Thomas H; Marks C; Green M; Fan Z; Modjtahedi H
Int J Oncol; 2008 Nov; 33(5):1107-13. PubMed ID: 18949375
[TBL] [Abstract][Full Text] [Related]
6. Dual silencing of type 1 insulin-like growth factor and epidermal growth factor receptors to induce apoptosis of nasopharyngeal cancer cells.
Yuan YL; Zhou XH; Song J; Qiu XP; Li J; Ye LF
J Laryngol Otol; 2008 Sep; 122(9):952-60. PubMed ID: 17908353
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of insulin-like growth factor-1 receptor tyrosine kinase are preferentially cytotoxic to nutrient-deprived pancreatic cancer cells.
Momose I; Kunimoto S; Osono M; Ikeda D
Biochem Biophys Res Commun; 2009 Feb; 380(1):171-6. PubMed ID: 19166817
[TBL] [Abstract][Full Text] [Related]
8. RBx10080307, a dual EGFR/IGF-1R inhibitor for anticancer therapy.
Tandon R; Senthil V; Nithya D; Pamidiboina V; Kumar A; Malik S; Chaira T; Diwan M; Gupta P; Venkataramanan R; Malik R; Das B; Dastidar SG; Cliffe I; Ray A; Bhatnagar PK
Eur J Pharmacol; 2013 Jul; 711(1-3):19-26. PubMed ID: 23639757
[TBL] [Abstract][Full Text] [Related]
9. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
[TBL] [Abstract][Full Text] [Related]
10. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
[TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
12. ATP non-competitive IGF-1 receptor kinase inhibitors as lead anti-neoplastic and anti-papilloma agents.
Steiner L; Blum G; Friedmann Y; Levitzki A
Eur J Pharmacol; 2007 May; 562(1-2):1-11. PubMed ID: 17376430
[TBL] [Abstract][Full Text] [Related]
13. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR Nanobodies.
Roovers RC; Laeremans T; Huang L; De Taeye S; Verkleij AJ; Revets H; de Haard HJ; van Bergen en Henegouwen PM
Cancer Immunol Immunother; 2007 Mar; 56(3):303-317. PubMed ID: 16738850
[TBL] [Abstract][Full Text] [Related]
14. Growth factor receptor interplay and resistance in cancer.
Jones HE; Gee JM; Hutcheson IR; Knowlden JM; Barrow D; Nicholson RI
Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S45-51. PubMed ID: 17259558
[TBL] [Abstract][Full Text] [Related]
15. Co-inhibition of epidermal growth factor receptor and type 1 insulin-like growth factor receptor synergistically sensitizes human malignant glioma cells to CD95L-induced apoptosis.
Steinbach JP; Eisenmann C; Klumpp A; Weller M
Biochem Biophys Res Commun; 2004 Aug; 321(3):524-30. PubMed ID: 15358139
[TBL] [Abstract][Full Text] [Related]
16. Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Desbois-Mouthon C; Cacheux W; Blivet-Van Eggelpoël MJ; Barbu V; Fartoux L; Poupon R; Housset C; Rosmorduc O
Int J Cancer; 2006 Dec; 119(11):2557-66. PubMed ID: 16988945
[TBL] [Abstract][Full Text] [Related]
17. Photodynamic targeting of EGFR does not predict the treatment outcome in combination with the EGFR tyrosine kinase inhibitor Tyrphostin AG1478.
Weyergang A; Kaalhus O; Berg K
Photochem Photobiol Sci; 2008 Sep; 7(9):1032-40. PubMed ID: 18754049
[TBL] [Abstract][Full Text] [Related]
18. Nanobody-shell functionalized thermosensitive core-crosslinked polymeric micelles for active drug targeting.
Talelli M; Rijcken CJ; Oliveira S; van der Meel R; van Bergen En Henegouwen PM; Lammers T; van Nostrum CF; Storm G; Hennink WE
J Control Release; 2011 Apr; 151(2):183-92. PubMed ID: 21262289
[TBL] [Abstract][Full Text] [Related]
19. Synergy of epidermal growth factor receptor kinase inhibitor AG1478 and ErbB2 kinase inhibitor AG879 in human colon carcinoma cells is associated with induction of apoptosis.
Zhou Y; Brattain MG
Cancer Res; 2005 Jul; 65(13):5848-56. PubMed ID: 15994962
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor-I (IGF-I) induces epidermal growth factor receptor transactivation and cell proliferation through reactive oxygen species.
Meng D; Shi X; Jiang BH; Fang J
Free Radic Biol Med; 2007 Jun; 42(11):1651-60. PubMed ID: 17462533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
